Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Petros PharmaceuticalsPTPI +6.67% EV-to-OCF is 0.26 as of Aug. 10, 2026. Among 1,006 Drug Manufacturers companies, Petros Pharmaceuticals ranks better than 70.28% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Petros Pharmaceuticals's Enterprise Value is $-1.55 Mil.
Petros Pharmaceuticals's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was $-5.86 Mil. Therefore, Petros Pharmaceuticals's EV-to-OCF for today is 0.26.
The historical rank and industry rank for Petros Pharmaceuticals's EV-to-OCF or its related term are showing as below:
PTPI'
s EV-to-OCF Range Over the Past 10 Years
Min: -3.98 Med: -0.58 Max: 0.95
Current: 0.26
During the past 7 years, the highest EV-to-OCF of Petros Pharmaceuticals was 0.95. The lowest was -3.98. And the median was -0.58.
PTPI's EV-to-OCF is ranked better than 70.28% of 1006
companies
in the Drug Manufacturers industry
Industry Median: 11.1
vs PTPI: 0.26
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Petros Pharmaceuticals's PE Ratio (TTM) for today is calculated as:
Petros Pharmaceuticals's share price for today is $0.0032.
Petros Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.156.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Petros Pharmaceuticals's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Petros Pharmaceuticals EV-to-OCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Petros Pharmaceuticals's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Petros Pharmaceuticals's EV-to-OCF falls into.
Petros Pharmaceuticals's current Enterprise Value is $-1.55 Mil.
Petros Pharmaceuticals's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-5.86 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Petros Pharmaceuticals (PTPI) has a EV-to-OCF of 0.26 as of Aug. 10, 2026. According to the industry distribution chart, Petros Pharmaceuticals ranks #299 out of 1006 companies in the Drug Manufacturers industry, placing it in the top 29.7%.
Is Petros Pharmaceuticals' EV-to-OCF too high?
Petros Pharmaceuticals' current EV-to-OCF is 0.26. The Drug Manufacturers industry median EV-to-OCF is 11.10. Petros Pharmaceuticals' value of 0.26 is 97.7% below this industry median. Based on the distribution chart, Petros Pharmaceuticals ranks #299 out of 1006 companies in the Drug Manufacturers industry, which is above the industry midpoint.
How does Petros Pharmaceuticals' EV-to-OCF compare to KOAN and KAYS?
According to the Drug Manufacturers industry distribution chart, Petros Pharmaceuticals ranks #299 out of 1006 companies for EV-to-OCF. This puts Petros Pharmaceuticals in the upper half of its industry. The industry median EV-to-OCF is 11.10. Petros Pharmaceuticals' value of 0.26 is 97.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Drug Manufacturers company?
The median EV-to-OCF among Drug Manufacturers companies is 11.10, based on 1,006 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Petros Pharmaceuticals's current EV-to-OCF of 0.26 is 97.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median EV-to-OCF is 11.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Petros Pharmaceuticals's current EV-to-OCF is 0.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Petros Pharmaceuticals stock overvalued right now?
Petros Pharmaceuticals (PTPI) has a current EV-to-OCF of 0.26. The current EV-to-OCF is 0.26 and 97.7% below the Drug Manufacturers industry median of 11.10. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Petros Pharmaceuticals (PTPI), the current EV-to-OCF is 0.26 as of Aug. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Petros Pharmaceuticals Inc is a men's health pharmaceutical company. The Company is working towards the goal of becoming an innovator in the emerging self-care market, driving expanded access to key nonprescription pharmaceuticals as Over-the-Counter and nonprescription drug products with additional conditions for nonprescription use (ACNU Products) treatment options. Petros is pursuing the development of a proprietary integrated technology solutions platform containing two components: SaaS, designed to assist pharmaceutical companies in operationalizing and commercializing an Rx-to-OTC switch as an element in the development of an ACNU Product, and a potential Software as a Medical Device component, which guides the consumer in navigating appropriate self-selection or deselection.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PTPI has been successfully added to your 
